Annual Report 2025

NOTESTOTHE CONSOLIDATED FINANCIAL STATEMENTS For the year ended 31 December 2025 82 The United Laboratories International Holdings Limited Annual Report 2025 5. REVENUE AND SEGMENT INFORMATION The Group is currently organised into three revenue streams, including Intermediate products, Bulk medicine and Finished products. Specifically, the Group’s reportable segments under HKFRS 8 are as follows: 1) Intermediate products – mainly represent sales of 6-Aminopenicillanic acid (“6-APA”) products and penicillin G potassium products; 2) Bulk medicine – mainly represent sales of amoxicillin products; and 3) Finished products – mainly represent sales of insulin series products, antibiotics products, ophthalmic products, veterinary drugs and license fee income. (i) Disaggregation of revenue from contracts with customers For the year ended 31 December 2025 Intermediate Bulk Finished Segments products medicine products Total Elimination Consolidated RMB’000 RMB’000 RMB’000 RMB’000 RMB’000 RMB’000 Types of products – 6-APA 1,205,858 – – 1,205,858 – 1,205,858 – Antibiotics products – 4,841,126 3,042,889 7,884,015 – 7,884,015 – Insulin products – – 1,881,466 1,881,466 – 1,881,466 – License fee income – – 1,442,210 1,442,210 – 1,442,210 – Others 406,496 59,318 331,264 797,078 – 797,078 Revenue from contracts with customers 1,612,354 4,900,444 6,697,829 13,210,627 – 13,210,627 Inter-segment sales 2,405,952 992,419 – 3,398,371 (3,398,371) – Segment revenue 4,018,306 5,892,863 6,697,829 16,608,998 (3,398,371) 13,210,627